PHI-101
Phase 1UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 15/100
15
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Trial Timeline
Jun 8, 2020 → May 21, 2022
NCT ID
NCT04842370About PHI-101
PHI-101 is a phase 1 stage product being developed by iBio for Relapsed or Refractory Acute Myeloid Leukemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04842370. Target conditions include Relapsed or Refractory Acute Myeloid Leukemia.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Acute Myeloid Leukemia were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04842370 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Relapsed or Refractory Acute Myeloid Leukemia